DNA damage and inhibition of akt pathway in MCF-7 cells and ehrlich tumor in mice treated with 1,4-naphthoquinones in combination with ascorbate

Oxidative Medicine and Cellular Longevity

Volumn 2015, Issue , 2015, Pages

  Ourique, Fabiana ^a   Kviecinski, Maicon R ^b   Felipe, Karina B ^a   Correia, João Francisco Gomes ^a   Farias, Mirelle S ^a   Castro, Luiza S E P W ^a   Grinevicius, Valdelúcia M A S ^a   Valderrama, Jaime ^c   Rios, David ^c   Benites, Julio ^c   Buc Calderon, Pedro ^d   Pedrosa, Rozangela Curi ^a  

^a FEDERAL UNIVERSITY OF SANTA CATARINA   (Brazil)

^b UNIVERSITY OF SOUTHERN SANTA CATARINA   (Brazil)

^c UNIVERSIDAD ARTURO PRAT   (Chile)

^d UNIVERSITÉ CATHOLIQUE DE LOUVAIN   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

CELLS; CYTOLOGY; KETONES; MAMMALS; TUMORS;

1 ,4-NAPHTHOQUINONES; ANTI-TUMOR ACTIVITIES; ANTITUMOR MECHANISMS; CARCINOMA CELLS; EHRLICH ASCITES CARCINOMA; MOLECULAR TOXICITIES; NAPHTHOQUINONES; OXIDATIVE CLEAVAGES;

DNA;

1,4 NAPHTHOQUINONE; ANTINEOPLASTIC AGENT; ASCORBIC ACID; DNA; DOXORUBICIN; FREE RADICAL; HISTONE H2AX; JUGLONE; MAMMALIAN TARGET OF RAPAMYCIN; PHENYLAMINONAPHTHOQUINONE 7; PHENYLAMINONAPHTHOQUINONE 9; PHOSPHOPROTEIN; PROTEIN INHIBITOR; PROTEIN KINASE B; REACTIVE OXYGEN METABOLITE; THIOBARBITURIC ACID; THIOBARBITURIC ACID REACTIVE SUBSTANCE; UNCLASSIFIED DRUG; 1,4-NAPHTHOQUINONE; H2AFX PROTEIN, HUMAN; HISTONE; NAPHTHOQUINONE;

ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CELL DIVISION; CELL LEVEL; CELL PROLIFERATION; CELL VIABILITY; COLONY FORMATION; CONTROLLED STUDY; CYTOTOXICITY; DNA DAMAGE; DNA FRAGMENTATION; DOUBLE STRANDED DNA BREAK; DRUG EFFECT; EHRLICH ASCITES TUMOR; GROWTH INHIBITION; HISTONE PHOSPHORYLATION; HUMAN; HUMAN CELL; IMMUNOBLOTTING; IN VITRO STUDY; IN VIVO STUDY; LIPID PEROXIDATION; MALE; MCF 7 CELL LINE; MOUSE; NONHUMAN; OXIDATIVE STRESS; PROTEIN CLEAVAGE; SIGNAL TRANSDUCTION; TUMOR GROWTH; UPREGULATION; ANIMAL; BAGG ALBINO MOUSE; CARCINOMA, EHRLICH TUMOR; CELL SURVIVAL; CHEMISTRY; DRUG EFFECTS; METABOLISM; PATHOLOGY; TUMOR CELL LINE;

MUS;

ANIMALS; ANTINEOPLASTIC AGENTS; ASCORBIC ACID; CARCINOMA, EHRLICH TUMOR; CELL LINE, TUMOR; CELL PROLIFERATION; CELL SURVIVAL; DNA DAMAGE; HISTONES; HUMANS; MALE; MCF-7 CELLS; MICE; MICE, INBRED BALB C; NAPHTHOQUINONES; PROTO-ONCOGENE PROTEINS C-AKT; REACTIVE OXYGEN SPECIES;

EID: 84924559929     PISSN: 19420900     EISSN: 19420994     Source Type: Journal    
DOI: 10.1155/2015/495305     Document Type: Article

References (70)

1. M. M. Gottesman, "Mechanisms of cancer drug resistance," Annual Review of Medicine, vol. 53, pp. 615-627, 2002.
2. M. S. Farias, C. T. Pich, M. R. Kviecinski et al, "Substituted 3-acyl-2-phenylamino-1, 4-naphthoquinones intercalate into DNA and cause genotoxicity through the increased generation of reactive oxygen species culminating in cell death," Molecular Medicine Reports, vol. 10, no. 1, pp. 405-410, 2014.
3. K. B. Felipe, J. Bénites, C. Glorieux et al., "Antiproliferative effects of phenylaminonaphthoquinones are increased by ascor-bate and associated with the appearance of a senescent pheno-type in human bladder cancer cells," Biochemical and Biophysical Research Communications, vol. 433, no. 4, pp. 573-578, 2013.
4. M. R. Kviecinski, R. C. Pedrosa, K. B. Felipe et al., "Inhibition of cell proliferation and migration by oxidative stress from ascorbate-driven juglone redox cycling in human bladder-derived T24 cells," Biochemical and Biophysical Research Communications, vol. 421, no. 2, pp. 268-273, 2012
5. C. F Thorn, C. Oshiro, S. Marsh et al., "Doxorubicin pathways: pharmacodynamics and adverse effects," Pharmacogenetics and Genomics, vol. 21, no. 7, pp. 440-446, 2011.
6. G. Bischoff and S. Hoffman, "DNA-binding of drugs used in medicinal therapies," Current Medicinal Chemistry, vol. 9, no. 3, pp. 321-348, 2002.
7. R. Palchaudhuri and P. J. Hergenrother, "DNA as a target for anticancer compounds: methods to determine the mode of binding and the mechanism of action," Current Opinion in Biotechnology, vol. 18, no. 6, pp. 497-503, 2007
8. M. S. Shahabuddin, M. Gopal, and S. C. Raghavan, "Intercalating and antitumor activity of 4 oxopyrimido [4,5:4,5]thieno(2, 3-b) quinoline-4(3H)-one," Journal of Cancer Molecules, vol. 3, pp. 139-146, 2007
9. Q. Chen, M. G Espey, M. C. Krishna et al., "Pharamacologic ascorbic acid concentrations selectively kill cancer cells: action as a pro-drug to deliver hydrogen peroxide to tissuse," Proceedings of the National Academy of Sciences of the United States of America, vol. 102, no. 38, pp. 13604-13609, 2005.
10. J. Du, J. J. Cullen, and G. R. Buettner, "Ascorbic acid: chemistry, biology and the treatment of cancer," Biochimica et Biophysica Acta, vol. 1826, no. 2, pp. 443-457, 2012.
11. M. G. Espey, P. Chen, B. Chalmers et al., "Pharmacologic ascorbate synergizes with gemcitabine in preclinical models of pancreatic cancer," Free Radical Biology and Medicine, vol. 50, no. 11, pp. 1610-1619, 2011.
12. J. Verrax, R. Beck, N. Dejeans et al., "Redox-active quinones and ascorbate: an innovative cancer therapy that exploits the vulnerability of cancer cells to oxidative stress," Anti-Cancer Agents in Medicinal Chemistry, vol. 11, no. 2, pp. 213-221, 2011.
13. J. Bénites, J. A. Valderrama, K. Bettega, R. C. Pedrosa, P. B. Calderon, and J. Verrax, "Biological evaluation of donor-acceptor aminonaphthoquinones as antitumor agents," European journal of Medicinal Chemistry, vol. 45, no. 12, pp. 6052-6057, 2010.
14. V. C. da Silveira, H. Benezra, J. S. Luz, R. C. Georg, C. C. Oliveira, and A. M. D. C. Ferreira, "Binding of oxindole-Schiff base copper(II) complexes to DNA and its modulation by the ligand," journal of Inorganic Biochemistry, vol. 105, no. 12, pp. 1692-1703, 2011.
15. T. Jun, W. Bochu, and Z. Liancai, "Hydrolytic cleavage of DNA by quercetin manganese(II) complexes," Colloids and Surfaces B: Biointerfaces, vol. 55, no. 2, pp. 149-152, 2007
16. N. P. Singh, M. T. McCoy, R. R. Tice, and E. L. Schneider, "A simple technique for quantitation of low levels of DNA damage in individual cells," Experimental Cell Research, vol. 175, no. 1, pp. 184-191, 1988.
17. J. Yuan, R. Adamski, and J. Chen, "Focus on histone variant H2AX: to be or not to be," FEBS Letters, vol. 584, no. 17, pp. 3717-3724, 2010.
18. T. T. Pauli, E. P. Rogakou, V. Yamazaki, C. U. Kirchgessner, M. Geliert, and W. M. Bonner, "A critical role for histone H2AX in recruitment of repair factors to nuclear foci after DNA damage," Current Biology, vol. 10, no. 15, pp. 886-895, 2000.
19. R. Lopez, A. Arumugam, R. Joseph et al., "Hyperglycemia enhances the proliferation of non-tumorigenic and malignant mammary epithelial cells through increased leptin/IGFIR signaling and activation of AKT/mTOR," PLoS ONE, vol. 8, no. 11, Article ID e79708, 2013.
20. G. M. Ross, T. J. McMillan, P. Wilcox, and A. R. Collins, "The single cell microgel electrophoresis assay (comet assay): technical aspects and applications. Report on the 5th LH Gray Trust Workshop, Institute of Cancer Research, 1994," Mutation Research, vol. 337, no. 1, pp. 57-60, 1995.
21. T. Mosmann, "Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays," Journal of Immunological Methods, vol. 65, no. 1-2, pp. 55-63, 1983.
22. N. A. P. Franken, H. M. Rodermond, J. Stap, J. Haveman, and C. van Bree, "Clonogenic assay of cells in vitro" Nature Protocols, vol. 1, no. 5, pp. 2315-2319, 2006.
23. C. Glorieux, N. Dejeans, B. Sid, R. Beck, P. B. Calderon, and J. Verrax, "Catalase overexpression in mammary cancer cells leads to a less aggressive phenotype and an altered response to chemotherapy," Biochemical Pharmacology, vol. 82, no. 10, pp. 1384-1390, 2011.
24. M. R. Kviecinski, P. Benelli, K. B. Felipe et al., "SFE from Bidens pilosa Linné to obtain extracts rich in cytotoxic polyacetylenes with antitumor activity," Journal of Supercritical Fluids, vol. 56, no. 3, pp. 243-248, 2011.
25. E. L. Kaplan and P. Meier, "Nonparametric estimation from incomplete observations," Journal of the American Statistical Association, vol. 53, pp. 457-481, 1958.
26. R. P. Bird and H. H. Draper, "Comparative studies on different methods of malonaldehyde determination," Methods in Enzymology, vol. 105, pp. 299-305, 1984.
27. V G. S. Box, "The intercalation of DNA double helices with doxorubicin and nagalomycin," Journal of Molecular Graphics and Modelling, vol. 26, no. 1, pp. 14-19, 2007
28. Q. Jiang, N. Xiao, P. Shi, Y Zhu, and Z. Guo, "Design of artificial metallonucleases with oxidative mechanism," Coordination Chemistry Reviews, vol. 251, no. 15-16, pp. 1951-1972, 2007
29. M. U. Rehman, M. Tahir, A. Q. Khan et al., "D-limonene suppresses doxorubicin-induced oxidative stress and inflammation via repression of COX-2, iNOS, and NFκB in kidneys of Wistar rats," Experimental Biology and Medicine, vol. 239, no. 4, pp. 465-476, 2014.
30. A. H. Boulares, A. G Yakovlev, V Ivanova et al., "Role of poly(ADP-ribose) polymerase (PARP) cleavage in apoptosis. Caspase 3-resistant PARP mutant increases rates of apoptosis in transfected cells," Journal of Biological Chemistry, vol. 274, no. 33, pp. 22932-22940, 1999.
31. N. Ahmad, S. Gupta, M. M. Husain, K. M. Heiskanen, and H. Mukhtar, "Differential antiproliferative and apoptotic response of sanguinarine for cancer cells versus normal cells," Clinical Cancer Research, vol. 6, no. 4, pp. 1524-1528, 2000.
32. S. J. Lee, H. Ahn, K. W. Nam, K. H. Kim, and W. Mar, "Effects of rutaecarpine on hydrogen peroxide-induced apoptosis in murine hepa-lclc7 cells," Biomolecules & Therapeutics, vol. 20, no. 5, pp. 487-491, 2012.
33. E.-S. A. Arafa, Q. Zhu, Z. I. Shah et al., "Thymoquinone up-regulates PTEN expression and induces apoptosis in doxorubicin-resistant human breast cancer cells," Mutation Research-Fundamental and Molecular Mechanisms of Mutagenesis, vol. 706, no. 1-2, pp. 28-35, 2011.
34. kipl by PKB/Akt-mediated phosphorylation in breast cancer," Nature Medicine, vol. 8, no. 10, pp. 1136-1144, 2002.
35. B. D. Clarkson and J. H. Burchenal, "Preliminary screening of antineoplastic drugs," Progress in Clinical Cancer, vol. 1, pp. 625-629, 1965.
36. M. M. Gottesman, "Mechanisms of cancer drug resistance," Annual Review of Medicine, vol. 53, pp. 615-627, 2002.
37. M. S. Farias, C. T. Pich, M. R. Kviecinski et al, "Substituted 3-acyl-2-phenylamino-1, 4-naphthoquinones intercalate into DNA and cause genotoxicity through the increased generation of reactive oxygen species culminating in cell death," Molecular Medicine Reports, vol. 10, no. 1, pp. 405-410, 2014.
38. K. B. Felipe, J. Bénites, C. Glorieux et al., "Antiproliferative effects of phenylaminonaphthoquinones are increased by ascor-bate and associated with the appearance of a senescent pheno-type in human bladder cancer cells," Biochemical and Biophysical Research Communications, vol. 433, no. 4, pp. 573-578, 2013.
39. M. R. Kviecinski, R. C. Pedrosa, K. B. Felipe et al., "Inhibition of cell proliferation and migration by oxidative stress from ascorbate-driven juglone redox cycling in human bladder-derived T24 cells," Biochemical and Biophysical Research Communications, vol. 421, no. 2, pp. 268-273, 2012
40. C. F Thorn, C. Oshiro, S. Marsh et al., "Doxorubicin pathways: pharmacodynamics and adverse effects," Pharmacogenetics and Genomics, vol. 21, no. 7, pp. 440-446, 2011.
41. G. Bischoff and S. Hoffman, "DNA-binding of drugs used in medicinal therapies," Current Medicinal Chemistry, vol. 9, no. 3, pp. 321-348, 2002.
42. R. Palchaudhuri and P. J. Hergenrother, "DNA as a target for anticancer compounds: methods to determine the mode of binding and the mechanism of action," Current Opinion in Biotechnology, vol. 18, no. 6, pp. 497-503, 2007
43. M. S. Shahabuddin, M. Gopal, and S. C. Raghavan, "Intercalating and antitumor activity of 4 oxopyrimido [4,5:4,5]thieno(2, 3-b) quinoline-4(3H)-one," Journal of Cancer Molecules, vol. 3, pp. 139-146, 2007
44. Q. Chen, M. G Espey, M. C. Krishna et al., "Pharamacologic ascorbic acid concentrations selectively kill cancer cells: action as a pro-drug to deliver hydrogen peroxide to tissuse," Proceedings of the National Academy of Sciences of the United States of America, vol. 102, no. 38, pp. 13604-13609, 2005.
45. J. Du, J. J. Cullen, and G. R. Buettner, "Ascorbic acid: chemistry, biology and the treatment of cancer," Biochimica et Biophysica Acta, vol. 1826, no. 2, pp. 443-457, 2012.
46. M. G. Espey, P. Chen, B. Chalmers et al., "Pharmacologic ascorbate synergizes with gemcitabine in preclinical models of pancreatic cancer," Free Radical Biology and Medicine, vol. 50, no. 11, pp. 1610-1619, 2011.
47. J. Verrax, R. Beck, N. Dejeans et al., "Redox-active quinones and ascorbate: an innovative cancer therapy that exploits the vulnerability of cancer cells to oxidative stress," Anti-Cancer Agents in Medicinal Chemistry, vol. 11, no. 2, pp. 213-221, 2011.
48. J. Bénites, J. A. Valderrama, K. Bettega, R. C. Pedrosa, P. B. Calderon, and J. Verrax, "Biological evaluation of donor-acceptor aminonaphthoquinones as antitumor agents," European journal of Medicinal Chemistry, vol. 45, no. 12, pp. 6052-6057, 2010.
49. V. C. da Silveira, H. Benezra, J. S. Luz, R. C. Georg, C. C. Oliveira, and A. M. D. C. Ferreira, "Binding of oxindole-Schiff base copper(II) complexes to DNA and its modulation by the ligand," journal of Inorganic Biochemistry, vol. 105, no. 12, pp. 1692-1703, 2011.
50. T. Jun, W. Bochu, and Z. Liancai, "Hydrolytic cleavage of DNA by quercetin manganese(II) complexes," Colloids and Surfaces B: Biointerfaces, vol. 55, no. 2, pp. 149-152, 2007
51. N. P. Singh, M. T. McCoy, R. R. Tice, and E. L. Schneider, "A simple technique for quantitation of low levels of DNA damage in individual cells," Experimental Cell Research, vol. 175, no. 1, pp. 184-191, 1988.
52. J. Yuan, R. Adamski, and J. Chen, "Focus on histone variant H2AX: to be or not to be," FEBS Letters, vol. 584, no. 17, pp. 3717-3724, 2010.
53. T. T. Pauli, E. P. Rogakou, V. Yamazaki, C. U. Kirchgessner, M. Geliert, and W. M. Bonner, "A critical role for histone H2AX in recruitment of repair factors to nuclear foci after DNA damage," Current Biology, vol. 10, no. 15, pp. 886-895, 2000.
54. R. Lopez, A. Arumugam, R. Joseph et al., "Hyperglycemia enhances the proliferation of non-tumorigenic and malignant mammary epithelial cells through increased leptin/IGFIR signaling and activation of AKT/mTOR," PLoS ONE, vol. 8, no. 11, Article ID e79708, 2013.
55. G. M. Ross, T. J. McMillan, P. Wilcox, and A. R. Collins, "The single cell microgel electrophoresis assay (comet assay): technical aspects and applications. Report on the 5th LH Gray Trust Workshop, Institute of Cancer Research, 1994," Mutation Research, vol. 337, no. 1, pp. 57-60, 1995.
56. T. Mosmann, "Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays," Journal of Immunological Methods, vol. 65, no. 1-2, pp. 55-63, 1983.
57. N. A. P. Franken, H. M. Rodermond, J. Stap, J. Haveman, and C. van Bree, "Clonogenic assay of cells in vitro" Nature Protocols, vol. 1, no. 5, pp. 2315-2319, 2006.
58. C. Glorieux, N. Dejeans, B. Sid, R. Beck, P. B. Calderon, and J. Verrax, "Catalase overexpression in mammary cancer cells leads to a less aggressive phenotype and an altered response to chemotherapy," Biochemical Pharmacology, vol. 82, no. 10, pp. 1384-1390, 2011.
59. M. R. Kviecinski, P. Benelli, K. B. Felipe et al., "SFE from Bidens pilosa Linné to obtain extracts rich in cytotoxic polyacetylenes with antitumor activity," Journal of Supercritical Fluids, vol. 56, no. 3, pp. 243-248, 2011.
60. E. L. Kaplan and P. Meier, "Nonparametric estimation from incomplete observations," Journal of the American Statistical Association, vol. 53, pp. 457-481, 1958.
61. R. P. Bird and H. H. Draper, "Comparative studies on different methods of malonaldehyde determination," Methods in Enzymology, vol. 105, pp. 299-305, 1984.
62. V G. S. Box, "The intercalation of DNA double helices with doxorubicin and nagalomycin," Journal of Molecular Graphics and Modelling, vol. 26, no. 1, pp. 14-19, 2007
63. Q. Jiang, N. Xiao, P. Shi, Y Zhu, and Z. Guo, "Design of artificial metallonucleases with oxidative mechanism," Coordination Chemistry Reviews, vol. 251, no. 15-16, pp. 1951-1972, 2007
64. M. U. Rehman, M. Tahir, A. Q. Khan et al., "D-limonene suppresses doxorubicin-induced oxidative stress and inflammation via repression of COX-2, iNOS, and NFκB in kidneys of Wistar rats," Experimental Biology and Medicine, vol. 239, no. 4, pp. 465-476, 2014.
65. A. H. Boulares, A. G Yakovlev, V Ivanova et al., "Role of poly(ADP-ribose) polymerase (PARP) cleavage in apoptosis. Caspase 3-resistant PARP mutant increases rates of apoptosis in transfected cells," Journal of Biological Chemistry, vol. 274, no. 33, pp. 22932-22940, 1999.
66. N. Ahmad, S. Gupta, M. M. Husain, K. M. Heiskanen, and H. Mukhtar, "Differential antiproliferative and apoptotic response of sanguinarine for cancer cells versus normal cells," Clinical Cancer Research, vol. 6, no. 4, pp. 1524-1528, 2000.
67. S. J. Lee, H. Ahn, K. W. Nam, K. H. Kim, and W. Mar, "Effects of rutaecarpine on hydrogen peroxide-induced apoptosis in murine hepa-lclc7 cells," Biomolecules & Therapeutics, vol. 20, no. 5, pp. 487-491, 2012.
68. E.-S. A. Arafa, Q. Zhu, Z. I. Shah et al., "Thymoquinone up-regulates PTEN expression and induces apoptosis in doxorubicin-resistant human breast cancer cells," Mutation Research-Fundamental and Molecular Mechanisms of Mutagenesis, vol. 706, no. 1-2, pp. 28-35, 2011.
69. kipl by PKB/Akt-mediated phosphorylation in breast cancer," Nature Medicine, vol. 8, no. 10, pp. 1136-1144, 2002.
70. B. D. Clarkson and J. H. Burchenal, "Preliminary screening of antineoplastic drugs," Progress in Clinical Cancer, vol. 1, pp. 625-629, 1965.